A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema (NCT07216027)
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin. The study is seeking participants who: 1. Are 18 to 64 years of age; 2. Were confirmed to have AD at least 6 months ago; 3. Do not have a suitable prescribed medicine for AD; 4. Are considered by their doctors to have moderate to severe AD. The study has two stages (Stage 1 and Stage 2). In both stages, eligible participants will take either PF-08049820 or placebo as tablets by mouth daily for 12 weeks. A placebo does not have any medicine in it but looks just like the medicine being studied. Participants will visit the clinic on Day 1, Weeks 1, 2, 4, 6, 8 and 12. They will have a follow-up visit at Week 16. During this time, the participant's health and skin condition will be checked. They will have blood and urine tests. They will also have to answer questions about their health, skin condition, and how much their skin condition affects their lives. The experiences of participants receiving the study medicine will be compared to those receiving placebo. This will help to understand if PF-08049820 is safe and effective.
Who can join: Review the eligibility criteria below.
Location: Marvel Clinical Research — Huntington Beach, California
Age range: 18 Years to 64 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- Marvel Clinical Research — Huntington Beach, California
- Metropolis Dermatology - DTLA — Los Angeles, California
- Northridge Clinical Trials — Northridge, California
- Clinical Science Institute — Santa Monica, California
- Gsi Clinical Research — Margate, Florida
- Skin Research of South Florida — Miami, Florida
- Montefiore - Jacobi Dermatology Clinic — The Bronx, New York
- Montefiore - Clinical Research Center — The Bronx, New York
- Montefiore - Greene Medical Arts Pavillion — The Bronx, New York
- Montefiore - The Dermatology Center — The Bronx, New York
- Montefiore Medical Center — The Bronx, New York
- UPMC Department of Dermatology — Pittsburgh, Pennsylvania
- Centre de Recherche Saint-Louis inc. — Québec,
- Huashan Hospital, Fudan University — Shanghai, Shanghai Municipality
- Hattori Dermatology Clinic — Takasaki, Gunma
- Kosugi Dermatology Clinic — Kawasaki-shi, Kanagawa
- Queen's square Medical Facilities Queen's square Dermatology and Allergology — Yokohama, Kanagawa
- Dermatology and Ophthalmology Kume Clinic — Sakai, Osaka
- Nihonbashi Sakura Clinic — Chuo-ku, Tokyo
- Fukuwa Clinic — Chuo-ku, Tokyo
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Atopic Dermatitis
- A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Birmingham, Alabama
- ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis — Phoenix, Arizona
- A Study of Barzolvolimab in Patients With Atopic Dermatitis — Birmingham, Alabama
- Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis — Chicago, Illinois
- A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis — Birmingham, Alabama
- A Study Evaluating APG777 in Atopic Dermatitis — Fountain Valley, California
Explore by condition: All Atopic Dermatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.